Grifols to Buy Talecris in $3 bn Deal

Spanish healthcare company Grifols SA will acquire Talecris Biotherapeutics, a producer of plasma-based protein therapies part-owned by Cerberus Capital Management, according to reports published Sunday and Monday. The deal is expected to be worth over $3 billion and is likely to be in cash and stock, with the majority in cash. Talecris has a market capitalization of nearly $2 billion, according to Reuters data. The Wall Street Journal earlier reported talks on the deal and said Cerberus and its co-investors could make a gain of more than $2 billion on their original investment.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.